PRME Prime Medicine Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRME

Price (delayed)

$3.13

Market cap

$567.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$619.05M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29
Highlights
The EPS has grown by 31% YoY and by 14% from the previous quarter
PRME's net income is up by 6% year-on-year and by 5% since the previous quarter
Prime Medicine's equity has decreased by 48% from the previous quarter and by 35% YoY
PRME's gross profit is down by 18% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://primemedicine.com
Peers: VRTX NTLA CRSP DNLI

Key stats

What are the main financial stats of PRME

PRME stock price

How has the Prime Medicine stock price performed over time
Intraday
-11.58%
1 week
4.33%
1 month
-7.67%
1 year
-41.93%
YTD
-9.8%
QTD
-15.18%

Financial performance

How have Prime Medicine's revenue and profit performed over time
Revenue
$4.07M
Gross profit
$4.07M
Operating income
-$196.52M
Net income
-$187.89M
Gross margin
100%
Net margin
-4,613.1%
PRME's gross profit is down by 18% YoY
PRME's revenue is down by 18% YoY
The operating margin has declined by 17% year-on-year but it has grown by 6% since the previous quarter
PRME's net margin is down by 15% year-on-year but it is up by 6% since the previous quarter

Price vs fundamentals

How does PRME's price correlate with its fundamentals

Growth

What is Prime Medicine's growth rate over time

Valuation

What is Prime Medicine stock price valuation
P/E
N/A
P/B
14.2
P/S
136.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
151.99
The EPS has grown by 31% YoY and by 14% from the previous quarter
PRME's price to book (P/B) is 85% higher than its last 4 quarters average of 8.7
Prime Medicine's equity has decreased by 48% from the previous quarter and by 35% YoY
PRME's revenue is down by 18% YoY
The P/S is 7% above the last 4 quarters average of 143.4

Efficiency

How efficient is Prime Medicine business performance
The return on invested capital has grown by 33% year-on-year and by 3.2% since the previous quarter
The return on equity has declined by 21% year-on-year
The ROS has contracted by 15% YoY but it has grown by 6% from the previous quarter
Prime Medicine's return on assets has increased by 8% YoY and by 3.1% QoQ

Dividends

What is PRME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRME.

Financial health

How did Prime Medicine financials performed over time
PRME's total assets is 19% greater than its total liabilities
Prime Medicine's current ratio has decreased by 20% QoQ and by 14% YoY
The quick ratio has decreased by 17% from the previous quarter
PRME's debt is 183% greater than its equity
Prime Medicine's debt to equity has surged by 90% QoQ and by 44% YoY
Prime Medicine's equity has decreased by 48% from the previous quarter and by 35% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.